Previous 10 | Next 10 |
Kinnate Biopharma (NASDAQ:KNTE) is set to join the NASDAQ Biotechnology Index. The move will be effective prior to market open on December 20, 2021. For further details see: Kinnate Biopharma to join NASDAQ Biotechnology Index
SAN FRANCISCO and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today...
Kinnate Biopharma (NASDAQ:KNTE): Q3 GAAP EPS of -$0.57 misses by $0.04. Revenue of $0M Press Release Ended the quarter with cash, cash equivalents and investments of $347.9 million, exclusive of its China joint venture’s cash. For further details see: Kinnate Biopharma ...
In collaboration with Guardant Health, announced initial findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study Ended the quarter with cash, cash equivalents and investments of $347.9 million, exclusive of its China joint venture’s c...
BRAF clinical-genomic landscape research initiative to investigate real-world data from more than 175,000 patients across tumor types, patient demographics and treatment settings Preliminary analyses found that more than half of the patients identified as having BRAF alterat...
Kinnate Biopharma (NASDAQ:KNTE) has announced that Chief Scientific Officer Eric Murphy is stepping down from the role, effective December 3, 2021. Murphy is leaving the firm to pursue a new opportunity, but has agreed to support the company by serving on its Scientific Advisory Board. For ...
SAN FRANCISCO and SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today...
SAN FRANCISCO and SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, will ...
SAN FRANCISCO and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, toda...
SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, anno...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...